Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
41
CABA Quote, Financials, Valuation and Earnings
Last price:
$2.20
Seasonality move
:
-11.03%
Day range:
$2.10 - $2.20
52-week range:
$0.99 - $3.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.51x
Volume:
1.2M
Avg. volume:
2.1M
1-year change:
-3.52%
Market cap:
$210.8M
Revenue:
--
EPS (TTM):
-$2.53
Analysts' Opinion
-
Consensus RatingCabaletta Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.13, Cabaletta Bio, Inc. has an estimated upside of 544.98% from its current price of $2.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 8.68% downside risk from its current price of $2.19.
Fair Value
-
According to the consensus of 9 analysts, Cabaletta Bio, Inc. has 544.98% upside to fair value with a price target of $14.13 per share.
CABA vs. S&P 500
-
Over the past 5 trading days, Cabaletta Bio, Inc. has overperformed the S&P 500 by 1.7% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cabaletta Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cabaletta Bio, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Cabaletta Bio, Inc. reported revenues of --.
Earnings Growth
-
Cabaletta Bio, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cabaletta Bio, Inc. reported earnings per share of -$0.44.
Enterprise value:
76.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-0.64x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.8M
Return On Assets:
-81.48%
Net Income Margin (TTM):
--
Return On Equity:
-103.46%
Return On Invested Capital:
-90.44%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$4.9M | -$1.6M | -$1.8M | -$424K | -$345K | |
| Operating Income | -$67.8M | -$114.5M | -$163.4M | -$33M | -$46.6M | |
| EBITDA | -$62.9M | -$112.9M | -$161.6M | -$32.6M | -$46.2M | |
| Diluted EPS | -$1.72 | -$2.16 | -$2.53 | -$0.62 | -$0.44 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $120.9M | $88.2M | $166.2M | $185.5M | $164.6M | |
| Total Assets | $122.6M | $91.7M | $173.3M | $204.4M | $189.8M | |
| Current Liabilities | $6M | $5.8M | $10.6M | $22.9M | $45.7M | |
| Total Liabilities | $6M | $5.8M | $12.4M | $30.2M | $50.3M | |
| Total Equity | $116.6M | $85.9M | $160.9M | $174.2M | $139.5M | |
| Total Debt | -- | -- | $1.7M | $7.3M | $22.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$49.2M | -$81.5M | -$118.9M | -$20.3M | -$34.5M | |
| Cash From Investing | -$23.9M | $36.3M | -$87.9M | $12.2M | -$50.1M | |
| Cash From Financing | $127.5M | $100.4M | $96.4M | $71K | -$806K | |
| Free Cash Flow | -$50.1M | -$83.6M | -$120.3M | -$20.6M | -$34.6M | |
CABA
Sector
Market Cap
$210.8M
$27.6M
Price % of 52-Week High
59.67%
50.06%
Dividend Yield
0%
0%
Shareholder Yield
-46.75%
-1.55%
1-Year Price Total Return
-3.52%
-18.12%
Beta (5-Year)
3.249
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.27
200-day SMA
Buy
Level
$1.91
Bollinger Bands (100)
Sell
Level
1.79 - 2.67
Chaikin Money Flow
Sell
Level
-45.6M
20-day SMA
Sell
Level
$2.37
Relative Strength Index (RSI14)
Sell
Level
42.65
ADX Line
Sell
Level
17.89
Williams %R
Neutral
Level
-78.0488
50-day SMA
Sell
Level
$2.46
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
134M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.9992)
Sell
CA Score
(Annual)
Level (-1.2805)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (5.0203)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Stock Forecast FAQ
In the current month, CABA has received 7 Buy ratings 2 Hold ratings, and 0 Sell ratings. The CABA average analyst price target in the past 3 months is $14.13.
-
Where Will Cabaletta Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cabaletta Bio, Inc. share price will rise to $14.13 per share over the next 12 months.
-
What Do Analysts Say About Cabaletta Bio, Inc.?
Analysts are divided on their view about Cabaletta Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cabaletta Bio, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Cabaletta Bio, Inc.'s Price Target?
The price target for Cabaletta Bio, Inc. over the next 1-year time period is forecast to be $14.13 according to 9 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is CABA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cabaletta Bio, Inc. is a Buy. 7 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CABA?
You can purchase shares of Cabaletta Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cabaletta Bio, Inc. shares.
-
What Is The Cabaletta Bio, Inc. Share Price Today?
Cabaletta Bio, Inc. was last trading at $2.20 per share. This represents the most recent stock quote for Cabaletta Bio, Inc.. Yesterday, Cabaletta Bio, Inc. closed at $2.19 per share.
-
How To Buy Cabaletta Bio, Inc. Stock Online?
In order to purchase Cabaletta Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CABA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CABA
Sector
P/E ratio
--
23.89x
PEG ratio
-0.05x
-0.01x
P/B ratio
1.51x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
CABA
Sector
Revenue growth
--
4.6%
Earnings growth
29.14%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.47
-$0.18
Profitability
CABA
Sector
Profitability FY 2024
-$4.8M
$3.6M
Return on invested capital
-90.44%
-31.84%
Return on assets
-81.48%
-27.96%
Return on equity
-103.46%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
9
Balance Sheet
CABA
Sector
Total cash
$159.9M
$26.3M
Short term investments
--
$25.7M
Total assets
$189M
$78M
Long term debt
$22.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
